Contineum Therapeutics Inc. (CTNM) has announced the results of its Phase 2 MOONLIGHT-1 trial, which evaluated the efficacy of JNJ-5120 (also known as PIPE-307) in patients with chronic obstructive pulmonary disease (COPD). The company disclosed that the trial did not meet its primary efficacy endpoint.
The filing details that analyses of the data, including prespecified exploratory endpoints, are currently ongoing. Contineum stated that further review of the results is required to determine the next steps for the program.
The company is a clinical-stage biopharmaceutical business focused on the development of small molecule drugs for the treatment of inflammatory and fibrotic diseases.
